Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
EP05.01 - Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
-
+
EP05.01-030 - CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany - AIO-TRK-0315
Presenter: Wilfried Ernst Erich Eberhardt- Abstract
Loading...
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-020 - Phase 2 Platform Trial of Anti-TIGIT GSK’859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)
Presenter: David Spigel- Abstract
Loading... -
+
EP08.01-057 - Pembrolizumab Maintenance in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sNSCLC) - AIO-TRK-0115/PRIMUS
Presenter: Martin Reck- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-060 - How Do Oncologists Treat Patients With EGFR Exon-20 Mutant NSCLC Outside of Clinical Trials? Updated Analysis From the European EXOTIC Registry
Presenter: Giannis Mountzios- Abstract
Loading... -
+
EP08.02-098 - Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab±Platinum in First-Line Metastatic NSCLC
Presenter: Martin Reck- Abstract
Loading...
-
+
EP14.01 - Small Cell Lung Cancer and Neuro-endocrine Tumors - Informing ES-SCLC
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Small Cell Lung Cancer and Neuro-endocrine Tumors - Informing ES-SCLC
-
+
EP14.01-015 - IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC
Presenter: Luis Paz-Ares- Abstract
Loading...
-
+
EP16.01 - Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
-
+
EP16.01-011 - PD-L1 Expression on Cytological Imprints and Circulating Tumor Cells versus Standardized Immunohistochemistry in NSCLC
Presenter: Martin Reck- Abstract
Loading...
-
+
P1.15 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 17:00 - 19:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
P1.15-05 - Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial)
Presenter: Martin Reck- Abstract
Loading...
-
+
ES25 - Clinical Issues with Immunotherapy in Non-small Cell Lung Cancer
- 16:00 - 17:00
- 8/08/2022
- Location: Hall C1
- IASLC CME Accredited
- Type: Education Session
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Moderators:Martin Reck, Sanjay Popat
-
+
Session Moderator
16:38 - 16:50 | Presenter: Martin Reck
- Abstract
Loading... -
+
Session Moderator
16:38 - 16:50 | Presenter: Sanjay Popat
- Abstract
Loading... -
+
ES25.01 - Session Introduction
16:00 - 16:01 | Presenter: Martin Reck
- Abstract
Loading... -
+
ES25.02 - Session Introduction
16:01 - 16:02 | Presenter: Sanjay Popat
- Abstract
Loading... -
+
ES25.03 - First-Line Choice in PD-L1 Positive Patients
16:02 - 16:14 | Presenter: Filiz Oezkan
- Abstract
Loading... -
+
ES25.04 - First-Line Choice in PD-L1 Negative Patients
16:14 - 16:26 | Presenter: Delvys Rodriguez-Abreu
- Abstract
Loading... -
+
ES25.05 - Second-Line Options in Immune-Pretreated Patients
16:26 - 16:38 | Presenter: Keunchil Park
- Abstract
Loading... -
+
ES25.06 - Immunotherapy in Oncogene-Addicted NSCLC
16:38 - 16:50 | Presenter: Francesco Passiglia
- Abstract
Loading... -
+
ES25.07 - Live Q&A
16:50 - 17:00
- Abstract
Loading...
-
+
OA15 - Patient Selection in Advanced NSCLC Immunotherapy
- 14:30 - 15:30
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Moderators:Pilar Garrido, António Araújo
-
+
OA15.03 - Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100
14:32 - 14:42 | Presenter: Martin Reck
- Abstract
Loading... -
+
OA15.06 - Pooled Analysis of Outcomes With Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
15:02 - 15:12 | Presenter: Delvys Rodriguez-Abreu
- Abstract
Loading...
